Holen Sie sich die Stockscreener-App
24.09
2.38%
0.56
Schlusskurs vom Vortag:
$23.53
Offen:
$24.41
24-Stunden-Volumen:
552.08K
Relative Volume:
1.65
Marktkapitalisierung:
$1.33B
Einnahmen:
$29.71M
Nettoeinkommen (Verlust:
$-69.15M
KGV:
-46.96
EPS:
-0.513
Netto-Cashflow:
$-52.28M
1W Leistung:
+23.79%
1M Leistung:
+29.45%
6M Leistung:
+64,658%
1J Leistung:
+64,658%
1-Tages-Spanne:
$23.38
$24.82
1-Wochen-Bereich:
$20.50
$25.26
52-Wochen-Spanne:
$14.72
$29.16
Aktis Oncology Inc Stock (AKTS) Company Profile
Firmenname
Aktis Oncology Inc
Sektor
Branche
Telefon
978-237-4380
Adresse
17 DRYDOCK AVENUE, BOSTON, NC
Compare AKTS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKTS
Aktis Oncology Inc
|
24.09 | 1.33B | 29.71M | -69.15M | -52.28M | -0.513 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-02-03 | Eingeleitet | BofA Securities | Buy |
| 2026-02-03 | Eingeleitet | JP Morgan | Overweight |
| 2026-02-03 | Eingeleitet | Leerink Partners | Outperform |
| 2026-02-03 | Eingeleitet | TD Cowen | Buy |
| 2024-01-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-09-06 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-01-24 | Eingeleitet | B. Riley Securities | Buy |
| 2021-02-02 | Bestätigt | Craig Hallum | Buy |
| 2021-01-15 | Bestätigt | Craig Hallum | Buy |
| 2019-09-18 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-07-10 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2019-05-13 | Bestätigt | Craig Hallum | Buy |
| 2019-02-05 | Bestätigt | Craig Hallum | Buy |
| 2019-02-05 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-12-18 | Eingeleitet | Craig Hallum | Buy |
| 2018-11-30 | Eingeleitet | Lake Street | Buy |
| 2018-06-22 | Eingeleitet | Loop Capital | Buy |
| 2018-02-09 | Eingeleitet | Drexel Hamilton | Buy |
Alle ansehen
Aktis Oncology Inc Aktie (AKTS) Neueste Nachrichten
Aktis is a strong buy at Raymond James on therapeutic platform - MSN
Aktis Oncology (AKTS) Gains Strong Buy Rating from Raymond James - GuruFocus
Aktis stock gains Strong Buy from Raymond James (AKTS:NASDAQ) - Seeking Alpha
AKTS Initiates Coverage On by Raymond James -- Rating Set to Str - GuruFocus
This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Benzinga
Raymond James initiates Aktis Oncology stock coverage with buy rating By Investing.com - Investing.com Canada
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company - AOL.com
Aktis Oncology, Inc. (AKTS) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
Rezolve AI, Bakkt, Seagate And Other Big Stocks Moving Higher On Friday - Benzinga
Aktis Oncology: Mini-Proteins With A Targeted Punch (NASDAQ:AKTS) - Seeking Alpha
Aktis Oncology (AKTS) Jefferies Global Healthcare Conference 2026 Summary - Quartr
AKTS: Advancing novel radiopharmaceuticals with strong early data, robust supply, and pipeline growth - TradingView
H.C. Wainwright Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $35 - Moomoo
H.C. Wainwright Maintains Aktis Oncology(AKTS.US) With Buy Rating, Raises Target Price to $35 - Moomoo
AKTS Maintained by HC Wainwright & Co. -- Price Target Raised to $35 - GuruFocus
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Bank of America Securities Remains a Buy on Aktis Oncology, Inc. (AKTS) - The Globe and Mail
AKTS Q1 2026 Earnings: Wider-than-Expected Loss but Stock Gains on Pipeline ProgressGrowth Acceleration Report - newsline.com
Aktis Oncology CEO to present new targeted radiopharmaceuticals at Jefferies Healthcare Conference - Pluang
Aktis Oncology to Present at the Jefferies Global Healthcare Conference - The Manila Times
a16z Capital Management, L.L.C.'s Aktis Oncology Inc(AKTS) Holding History - GuruFocus
A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound - Yahoo Finance
Top Premarket Gainers - Moomoo
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors - The Manila Times
Aktis Oncology reports promising first-in-human... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Aktis Oncology to Present Promising AKY-2519 Data Targeting B7-H3 Tumors at 2026 ASCO Annual Meeting - Quiver Quantitative
Aktis Oncology Reports First-in-Human Clinical Imaging and - GlobeNewswire
New cancer agent shows high tumor uptake, limited healthy exposure - Stock Titan
Top Cybin (HELP) Competitors 2026 - MarketBeat
BofA Securities Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Blue Owl discloses 5.92% stake in Aktis Oncology (AKTS) in Schedule 13G - Stock Titan
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company - The Motley Fool
AKTS: Advancing miniprotein radioconjugates for cancer, with strong pipeline, partnerships, and cash runway - TradingView
AKTS: Miniprotein radiopharmaceuticals advance in oncology with strong clinical and financial momentum - TradingView
Bank of America Securities Reaffirms Their Buy Rating on Aktis Oncology, Inc. (AKTS) - The Globe and Mail
Biotech’s IPO tide is finally turning, thanks in part to the recent M&A surge - BioSpace
William Blair Maintains Aktis Oncology(AKTS.US) With Buy Rating - Moomoo
TD Cowen Maintains Aktis Oncology(AKTS.US) With Buy Rating - Moomoo
Aktis: Q1 Earnings Snapshot - 10TV
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 - The Manila Times
Aktis Oncology Q1 net loss widens on increased IPO-related expenses - TradingView
Aktis Oncology (NASDAQ: AKTS) boosts cash to $538.5M after IPO despite higher Q1 loss - Stock Titan
Aktis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Aktis Oncology (NASDAQ: AKTS) boosts cash with IPO, posts wider Q1 loss - Stock Titan
Earnings Flash (AKTS) Aktis Oncology, Inc. Reports Q1 Revenue $3.2M - Moomoo
Cancer radiopharma firm Aktis adds $365M IPO cash, funds to 2029 - Stock Titan
Aktis Oncology to Present at the BofA Securities Health Care Conference - GlobeNewswire
Aktis initiates phase 1b trial of AKY-2519 in prostate cancer By Investing.com - Investing.com India
Aktis Oncology CEO to present new targeted radiopharmaceuticals at BofA Health Care Conference - Pluang
William Blair Initiates Aktis Oncology(AKTS.US) With Buy Rating - Moomoo
AKTS: AKY-2519 advances in Phase I-B trials for mCRPC and B7H3-expressing tumors, with key data ahead - TradingView
Finanzdaten der Aktis Oncology Inc-Aktie (AKTS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):